Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Anemia in End Stage Renal Disease
Interventions
DRUG

FG-4592

TIW dosing, capsule

DRUG

Epoetin Alfa

TIW

Trial Locations (9)

Unknown

Peking Union Medical College Hospital, Beijing

Peking University First Hospital, Beijing

First Affiliated Hospital, Sun Yat-Sen University, Guangzhou

Zhejiang University No 1. Hospital, Hangzhou

Chang Zheng Hospital, Shanghai

Renji Hospital, Shanghai

RuiJin Hospital, Shanghai

XinHua Hospital, Shanghai

ShenZhen People's Hospital, Shenzhen

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

collaborator

RenJi Hospital

OTHER

collaborator

Chang Zheng Hospital

UNKNOWN

collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

collaborator

Peking University First Hospital

OTHER

collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

Shenzhen People's Hospital

OTHER

lead

FibroGen

INDUSTRY